Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

Seaport Therapeutics Presents Data Further Validating GlyphTM Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BAMF Health Doses First Patient in Promising New Prostate Cancer Alpha Radioligand Therapy Clinical Trial

Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Tango Therapeutics Announces $225 Million Financing

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform 

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Fierce Biotech Names Trace Neuroscience a “Fierce 15” Biotech Company of 2025

Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree

Seaport Therapeutics to Participate in Upcoming Investor Conferences

Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001

insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizuresra

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseasesse

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights